BIA unveils new data: UK leads Europe in cell and gene therapy as sector makes significant strides  

The UK is cementing its position as a global leader in cell and gene therapy, according to a new report released today by the UK BioIndustry Association (BIA), in collaboration with Citeline.  

The report, packed with fresh data insights, reveals a robust sector with significant investment, the highest number of clinical trials in Europe, and NHS patients benefitting from these life-changing treatments. 

The report highlights include: 

  • Investment hotspot: UK companies secured 55% of Europe's cell and gene therapy VC funding in 2023, showcasing the strength of the UK ecosystem. 
  • Clinical trial leader: With 84 drugs in clinical development, the UK surpasses all other European countries, offering patients early access to these innovative therapies. 
  • Turning promise into reality: 23 cell and gene therapies are already approved for patient use in the UK, demonstrating the sector's ability to deliver tangible benefits. 
  • UK companies driving innovation: Case studies of Autolus, Purespring Therapeutics, Orchard Therapeutics and Rinri Therapeutics 

Steve Bates, BIA CEO, said: 

"The UK's cell and gene therapy sector isn't just about research. It's about real-world impact. In 2022, we saw companies like Autolus and Orchard, born from the ingenuity of UK institutions like UCL, translate their pioneering work into tangible results. Orchard's gene therapy reaching newborns with MLD exemplifies the extraordinary potential of this field. These are not just advancements – they are stories of lives saved, transformed, and empowered. The UK's leadership in cell and gene therapy is a testament to our unwavering dedication to patient-centric advancements that rewrite the boundaries of healthcare." 

The report also acknowledges challenges facing the sector, including around manufacturing, talent, and patient access. BIA emphasises its commitment to collaboration with stakeholders to address these hurdles and ensure the UK remains a global leader in this field. 

"We're working closely with the government, NHS, and industry to overcome these challenges and ensure long-term success," said Bates. "Together, we can unlock the full potential of cell and gene therapies to improve the lives of patients in the UK and around the world." 


Notes to Editors 


More news and updates 

Deep Biotech will deliver a more sustainable future, and BIA is its new voice

Deep Biotech encompasses innovative companies harnessing the power of engineering biology to tackle humanity's most pressing challenges, from environmental pollution to climate change. From cultivating meat without animals to crafting bio-based materials that replace harmful plastics, Deep Biotech offers a sustainable roadmap for a greener future. 

Professor Sir Mene Pangalos wins Lifetime Achievement Award at the BIA’s Gala Dinner

Mene led AstraZeneca's pharmaceutical discovery and early development through a key period of growth and innovation and was a driving force for scientific excellence and collaboration. Joining the company in 2010, Mene transformed AstraZeneca’s approach to R&D, fostering deeper academic and industry partnerships, pioneering Open Innovation programmes, and building a culture that values truth-seeking in science.

Resilient UK biotech sector lands £1.8 billion investment in 2023

New report highlights sector's strength, investor confidence and long-term returns. London-quoted biotechs also continue to outperform UK and US markets over the long term, having made substantial gains during the pandemic that have not been lost.   

BIA unveils new data: UK leads Europe in cell and gene therapy as sector makes significant strides  

The UK is cementing its position as a global leader in cell and gene therapy, according to a new report released today by the UK BioIndustry Association (BIA), in collaboration with Citeline.  

BIA reaches 600 member companies, announces new board and leadership restructure 

The UK’s innovative trade association for life science and biotech companies, BioIndustry Association (BIA), today announces that it has reached 600 companies in membership for the first time ever, alongside new Board and staff appointments for 2024.

BIA announces its Charity Partnership for 2024 with RNID

BIA is thrilled to announce its charity partnership of the year for 2024 with RNID, the national charity supporting the 12 million people in the UK who are deaf, have hearing loss or tinnitus. 

BIA responds to the Chancellor's Autumn Statement 2023

Life science spin-outs, start-ups and scale-ups are key drivers of the UK’s innovation-based economy and crucial for discovering and developing new medicines to save lives in the NHS. The UK is home to a third of life science startups founded in Europe since 2012 and companies like them are responsible for nearly two-thirds of medicines being developed globally.

bioProcessUK to celebrate biotech’s shining stars 

The BioIndustry Association (BIA) will honour two distinguished individuals for their exceptional contributions to the innovative life sciences and biotech sector.

UK biotech fundraising picks up with best quarterly total since 2021

The UK biotech sector secured a substantial total of £563 million in venture capital and public financing during the three months spanning June to August 2023, data published today by the UK BioIndustry Association (BIA) and Clarivate shows.

Rare disease companies call for UK leadership in supporting access to new treatments

A group of companies developing innovative new medicines for rare diseases, working together through their trade association, is calling for the UK to lead greater collaboration between stakeholders, and uptake of best practice both in the UK and internationally, to improve access to new treatments for patients.


More within